A5028832593- Neuroblastoma Research and Treatments
- Sarcoma Diagnosis and Treatment
- Web and Library Services
- Cancer therapeutics and mechanisms
- Information Retrieval and Search Behavior
- Library Science and Administration
- Health, Environment, Cognitive Aging
- Healthcare Policy and Management
- Library Science and Information Literacy
- CAR-T cell therapy research
- Education and Critical Thinking Development
- Healthcare Systems and Public Health
- Open Education and E-Learning
- Library Collection Development and Digital Resources
- Topic Modeling
- Education Systems and Policy
- Cancer Genomics and Diagnostics
- Emergency and Acute Care Studies
- Virus-based gene therapy research
- Hospital Admissions and Outcomes
- Misinformation and Its Impacts
- Privacy, Security, and Data Protection
- Natural Language Processing Techniques
- Health and Lifestyle Studies
- Educational Methods and Media Use
Baylor College of Medicine
2013-2024
Texas Children's Hospital
2013-2024
Children's Cancer Center
2013-2024
Dan L Duncan Comprehensive Cancer Center
2024
University of Calgary
2023
Pediatrics and Genetics
2022
Houston Methodist
2021
Methodist Hospital
2021
Michael E. DeBakey VA Medical Center
2016
The University of Texas at Austin
2016
Subsequent malignancies are well-documented complications in long-term follow-up of cancer patients. Recently, genetically modified immune effector (IE) cells have shown benefit hematologic and being evaluated clinical trials for solid tumors. Although the short-term IE well described, there is limited literature summarizing follow-up, including subsequent malignancies. We retrospectively reviewed data from 340 patients treated across 27 investigator-initiated pediatric adult at our center....
OBJECTIVES: To determine pediatric program director (PD) approval and perception of changes to resident training patient care resulting from 2011 Accreditation Council for Graduate Medical Education (ACGME) Common Program Requirements. METHODS: All US PDs (n = 181) were identified the ACGME. Functional e-mail addresses 164 (90.6%). Three individualized requests sent each PD complete an anonymous 32-question Web-based survey. RESULTS: A total 151 responses obtained (83.4%). Pediatrics...
High-risk neuroblastoma is an aggressive childhood cancer with poor outcomes. Treatment begins induction phase comprised of intense multi-agent chemotherapy the goal maximally reducing tumor bulk. Given high intensity chemotherapy, neutropenic fever and infectious complications are common; however, actual incidence difficult to determine from clinical trial reports. We performed a retrospective review infection-related in 76 children treated for high-risk at Texas Children's Hospital....
Abstract Background Health disparities related to race, ethnicity, socioeconomic status, and insurance status impact quality, access, health outcomes for children. Medicaid is a proxy poverty restricted access care. The goal of this study was determine if there are discrepancies in the length cost hospitalizations between admissions covered by or commercial pediatric patients with cancer. Methods Childhood cancer‐related were identified from 2012 Kids Inpatient Database (KID) using...
Outcomes for children with high-risk neuroblastoma are poor, and improved understanding of the mechanisms underlying pathogenesis, recurrence, treatment resistance will lead to outcomes. Aberrant growth factor receptor expression tyrosine kinase signaling associated pathogenesis many malignancies. A germline polymorphism in FGFR4 gene is increased activity decreased survival, resistance, aggressive disease We therefore investigated role this pathogenesis.Germline DNA from patients matched...
BackgroundUBE4B is an E3/E4 ubiquitin ligase whose gene located in chromosome 1p36.22.We analyzed the associations of UBE4B and protein expression with neuroblastoma patient outcomes tumor prognostic features histology. MethodsWe evaluated association using R2 Platform.We screened samples for immunohistochemistry. FISH 1p36 deletion was performed on samples.We then factors levels phosphorylated ERK tumors cell lines. ResultsLow associated poor patients worse all subgroups.UBE4B...
IntroductionGlobally, differences in coding practices and guidelines lead to variations hospital-administrative data. Studies on patient safety found that better hospital-data quality is associated with higher rates of events. This study outlines our process creating a standardized tool for countries assess their data quality. ApproachWe developed 24 indicators across five different dimensions through Delphi-consensus method. To test applicability these indicators, we approached...
The combination of ifosfamide and etoposide (IE) is commonly used to treat relapsed or refractory osteosarcoma; however, second-line treatment recommendations vary across guidelines.
Abstract Osteosarcoma is the most common bone tumor in children and young adults. Metastatic relapsed disease confer poor prognosis, there have been no improvements outcomes for several decades. The disease's biological complexity, lack of drugs developed specifically osteosarcoma, imperfect preclinical models, limits existing clinical trial designs contributed to progress. Children's Oncology Group Bone Tumor Committee established New Agents Task Force identify prioritize agents inclusion...
Alberta has rich clinical and health services data held under the custodianship of Health Services (AHS), which is not only used for administrative purposes but also disease surveillance epidemiological research. largest province in Canada with a single payer centralised system, AHS, consolidated analytics team supporting researchers across province. This paper describes Alberta's custodians, governance mechanisms, streamlined processes followed research access. AHS created repository from...
Sarcomas with BCOR alteration are a heterogenous group characterized by changes including internal tandem duplications (ITDs) and recurring fusions CCNB3, ZC3H7B, other rare partners. With widespread genomic testing, these alterations now associated histologies such as Ewing-like sarcoma (BCOR::CCNB3), high-grade endometrial stromal (ZC3H7B::BCOR), clear cell of kidney (BCOR-ITD). altered sarcomas soft tissues organs were identified through PubMed using keywords "Sarcoma (AND) BCOR" from...
10521 Background: Outcomes for recurrent osteosarcoma are poor and novel therapies needed. Osteosarcoma has a high mutational burden with overexpression of PD-L1 in metastatic lesions, providing rationale testing immune checkpoint inhibitors this population. We therefore evaluated the activity inhibitor avelumab patients or progressive osteosarcoma. Methods: conducted single-arm, open-label phase 2 trial at 4 collaborating institutions. Eligible subjects were ages 12 to ≤50 years...
Abstract Introduction: Tegavivint is a first in class small molecule inhibitor of Wnt-ß-catenin signaling that functions by disrupting the interaction ß-catenin and TBL1/TBLR1 resulting degradation nuclear ß-catenin. Aberrant Wnt has been identified as key mechanism cancer biology, uncontrolled transcription pro-oncogenic target genes. Pre-clinical vivo studies tegavivint demonstrated anti-tumor activity variety pediatric solid tumors, including osteosarcoma, Ewing sarcoma, lymphoma....
Background: Despite advances in supportive measures, myeloablative chemotherapy with stem cell rescue remains limited by toxicity and treatment-related mortality. The purpose of this study was to identify factors influencing the rate hematopoietic recovery following autologous transplant high-risk neuroblastoma. Procedure: We retrospectively studied 54 patients neuroblastoma who received a single between 2006 2016. Race, sex, conditioning regimen, delays bone marrow involvement were analyzed...